On this page
Back to topLatigo Biotherapeutics LTGO
Latigo Biotherapeutics listed on Nasdaq on 7 Aug 2026 and is not in the S&P 500. It is worth $878 million. Its board is not in our data yet.
- Listed
- 7 Aug 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Thousand Oaks, CA
- Market cap
- $878M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Board and leadership
Board and officers
Latigo Biotherapeutics's board is not in our data yet. It listed on 7 Aug 2026 and has not filed a proxy statement. See its 8-K filings.
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $2.5 million in 1 purchase in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 10 Aug 2026Buy | James B. TananbaumDirector | $2.5M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
2 departures and 1 appointment of directors and officers in the last two years.
Events, newest first
- 3 Nov 2026 Nima Farzan resignedMember of the Board
- 3 Nov 2026 Nima Farzan leftPresident and Chief Executive Officer
- 3 Nov 2026 Todd Smith appointedPresident and Chief Executive Officer
Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings. 13F holdings: Latigo Biotherapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.